Studies on angiotensin II and analogs: impact of substitution in position 8 on conformation and activity. 1985

A Aumelas, and C Sakarellos, and K Lintner, and S Fermandjian, and M C Khosla, and R R Smeby, and F M Bumpus

Affinity, residual agonist activity, and inhibitor properties of a series of angiotensin II analogs modified at the COOH-terminal position (X8-substituted peptides) have been probed for structure/conformation-biological activity relationships. The results emphasize (i) the large impact that subtle conformational variations caused by structural alterations in the position 8 side chain have on biological properties, (ii) the implication of the COOH-terminal carboxyl group in both affinity and intrinsic activity, and (iii) the influence that the bulkiness of the side chain in position 8 of antagonists has on the local conformation at the COOH terminus and thus on the inhibitory properties. In the hormone, the phenylalanine-8 ring is required for its steric influence and aromaticity to ensure a fully active conformation at the COOH terminus. Especially, correct orientation of the position 8 carboxyl group relative to the phenyl group of the phenylalanine residue may be necessary for agonistic activation of the angiotensin receptor complex. Replacement of the aromatic ring on the COOH-terminal residue by a nonaromatic group leads to incorrect orientation of the carboxyl group and causes the appearance of antagonist properties. Although the steric effects of the side chain can be modulated by specific interaction of its chemical groups (if any) with the peptide backbone, we found a good correlation between the size of the side chain-e.g., the steric parameter V gamma (the van der Waals volume consisting of the C alpha, C beta, and C gamma atoms), the conformational properties in the backbone (3J HC alpha-NH), and the binding capacities in all compounds tested.

UI MeSH Term Description Entries
D009682 Magnetic Resonance Spectroscopy Spectroscopic method of measuring the magnetic moment of elementary particles such as atomic nuclei, protons or electrons. It is employed in clinical applications such as NMR Tomography (MAGNETIC RESONANCE IMAGING). In Vivo NMR Spectroscopy,MR Spectroscopy,Magnetic Resonance,NMR Spectroscopy,NMR Spectroscopy, In Vivo,Nuclear Magnetic Resonance,Spectroscopy, Magnetic Resonance,Spectroscopy, NMR,Spectroscopy, Nuclear Magnetic Resonance,Magnetic Resonance Spectroscopies,Magnetic Resonance, Nuclear,NMR Spectroscopies,Resonance Spectroscopy, Magnetic,Resonance, Magnetic,Resonance, Nuclear Magnetic,Spectroscopies, NMR,Spectroscopy, MR
D011487 Protein Conformation The characteristic 3-dimensional shape of a protein, including the secondary, supersecondary (motifs), tertiary (domains) and quaternary structure of the peptide chain. PROTEIN STRUCTURE, QUATERNARY describes the conformation assumed by multimeric proteins (aggregates of more than one polypeptide chain). Conformation, Protein,Conformations, Protein,Protein Conformations
D002942 Circular Dichroism A change from planar to elliptic polarization when an initially plane-polarized light wave traverses an optically active medium. (McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed) Circular Dichroism, Vibrational,Dichroism, Circular,Vibrational Circular Dichroism
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000804 Angiotensin II An octapeptide that is a potent but labile vasoconstrictor. It is produced from angiotensin I after the removal of two amino acids at the C-terminal by ANGIOTENSIN CONVERTING ENZYME. The amino acid in position 5 varies in different species. To block VASOCONSTRICTION and HYPERTENSION effect of angiotensin II, patients are often treated with ACE INHIBITORS or with ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS. Angiotensin II, Ile(5)-,Angiotensin II, Val(5)-,5-L-Isoleucine Angiotensin II,ANG-(1-8)Octapeptide,Angiotensin II, Isoleucine(5)-,Angiotensin II, Valine(5)-,Angiotensin-(1-8) Octapeptide,Isoleucine(5)-Angiotensin,Isoleucyl(5)-Angiotensin II,Valyl(5)-Angiotensin II,5 L Isoleucine Angiotensin II,Angiotensin II, 5-L-Isoleucine
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships

Related Publications

A Aumelas, and C Sakarellos, and K Lintner, and S Fermandjian, and M C Khosla, and R R Smeby, and F M Bumpus
October 1972, Journal of medicinal chemistry,
A Aumelas, and C Sakarellos, and K Lintner, and S Fermandjian, and M C Khosla, and R R Smeby, and F M Bumpus
January 1978, Proceedings of the Western Pharmacology Society,
A Aumelas, and C Sakarellos, and K Lintner, and S Fermandjian, and M C Khosla, and R R Smeby, and F M Bumpus
April 1974, Journal of medicinal chemistry,
A Aumelas, and C Sakarellos, and K Lintner, and S Fermandjian, and M C Khosla, and R R Smeby, and F M Bumpus
March 1974, Journal of medicinal chemistry,
A Aumelas, and C Sakarellos, and K Lintner, and S Fermandjian, and M C Khosla, and R R Smeby, and F M Bumpus
July 1974, Journal of theoretical biology,
A Aumelas, and C Sakarellos, and K Lintner, and S Fermandjian, and M C Khosla, and R R Smeby, and F M Bumpus
February 1983, Biopolymers,
A Aumelas, and C Sakarellos, and K Lintner, and S Fermandjian, and M C Khosla, and R R Smeby, and F M Bumpus
September 1981, Biopolymers,
A Aumelas, and C Sakarellos, and K Lintner, and S Fermandjian, and M C Khosla, and R R Smeby, and F M Bumpus
September 1972, Circulation research,
A Aumelas, and C Sakarellos, and K Lintner, and S Fermandjian, and M C Khosla, and R R Smeby, and F M Bumpus
July 1986, Archives of biochemistry and biophysics,
A Aumelas, and C Sakarellos, and K Lintner, and S Fermandjian, and M C Khosla, and R R Smeby, and F M Bumpus
May 1973, Journal of medicinal chemistry,
Copied contents to your clipboard!